On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for use in adults with specific conditions.Patients with advanced, unr...
targeted-cancer-therapies
On November 15, 2024, the Food and Drug Administration sanctioned revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia characterized by a ...
targeted-cancer-therapies
On September 25, 2024, the Food and Drug Administration sanctioned osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small ce...
targeted-cancer-therapies
The UCLA Johnson Cancer Centre, which is officially called the Jonsson Comprehensive Cancer Centre (JCCC), is one of the best places to study, treat, and care for people with cancer. The centre is in...
targeted-cancer-therapies